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Abstract 
Iatrogenic Cushing syndrome induced by oral and parenteral corticosteroid 
administration is a well-known complication and necessary precautions have to be taken. 
Cushing syndrome, however, following treatment with glucocorticoid-containing eye drops is 
a very rare complication. To the best of our knowledge there have been only 4 reported cases 
in the literature. Herein, we present an infant boy who developed Cushing syndrome after 
receiving dexamethasone-containing eye drops after bilateral cataract extraction to prevent 
post-operative inflammatory complications. At the age of 5 months, after approx. 3 months of 
dexamethasone therapy, the patient presented with cushingoid facies, nephrocalcinosis, and 
failure to grow. Iatrogenic Cushing syndrome was diagnosed and dexamethasone-containing 
eye drops were reduced and eventually stopped. Follow-up examinations revealed catch-up 
growth.  
Conclusion: Ocularly administered corticosteroids may have substantial systemic side effects 
in infants. 
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What is known – What is knew 
We present an illustrative and didactic case of Cushing syndrome in an infant due to 
dexamethasone-containing eye drops. So far, only four cases have been reported in children in 
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the literature (age range: 11 months to 18 years). The aim of the presented case report is to 
alert paediatricians to this rare complication of ocular administered glucocorticoids. 
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Introduction 
Cushing syndrome is the result of prolonged exposure to inappropriately high levels of 
endogenous or exogenous (iatrogenic) glucocorticoids. The latter is most commonly induced 
by prolonged exogenous oral or parenteral administered glucocorticoid hormones and 
represents the most frequent form of Cushing syndrome in children. However, iatrogenic 
Cushing syndrome in infants due to topical glucocorticoid administration is rare and may be 
underreported (10, 12).  
Topical steroids have a wide application in the treatment of postoperative ocular 
inflammations. Congenital cataract is one of the few visually handicapping disorders that is 
amenable to early lensectomy, but requires postoperative topical steroid treatment in order to 
prevent fibrinous uveitis. Cushing syndrome as a result of topical ocular steroids is extremely 
rare and we are aware of only four reported cases in infancy and childhood (3, 8, 9, 11). 
Herein, we present a case of iatrogenic Cushing syndrome in a 5 month old infant induced by 
dexamethasone-containing eye drops.  
 
Case report 
The patient was born at term (37 3/7 weeks of gestation) after an uneventful non-
identical twin pregnancy with isolated bilateral nuclear cataract of unknown aetiology (no 
cataract was observed in his twin sister). He was an otherwise healthy newborn with normal 
intrauterine growth (birth weight: 2840 g, birth length: 49 cm) without evidence for 
congenital infection. Bilateral cataract extraction was performed at the age of 6 weeks to 
improve visual prognosis. Immediately after uncomplicated surgery he was started on 
dexamethasone-containing eye drops (0.1% solution) to prevent fibrinous uveitis. He received 
one drop per eye every 2 hours for the first two weeks, thereafter dexamethasone dose was 
tempered as shown (Table 1). 
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At the age of 3 months breastfeeding was stopped and adapted formula milk was 
introduced instead. One month later he progressively started to refuse nutrition resulting in 
gradually stagnation of growth parameters (Figure 1A). At 5 months of age, the boy was 
hospitalized for acute viral gastroenteritis. On physical examination both body weight and 
length were below the 3rd percentile. He presented with prominent chubby plethoric cheeks 
(Figure 1B) and light hair growth on ears and scrotum. His blood pressure was normal 
(101/59 mm Hg). Unfortunately, bone age was not determined. Laboratory evaluation 
revealed normal sodium and potassium levels (sodium 138 mmol/l, potassium 4.6 mmol/l), 
low cortisol (morning: 5 nmol/l; afternoon: 3 nmol/l; reference range > 64 nmol/l) and ACTH 
levels (10 pg/ml; reference range: 10-55 pg/ml). In the context of diagnostic work-up for the 
patient’s failure to thrive abdominal ultrasonography was performed, which revealed 
nephrocalcinosis in both kidneys and left-sided hydronephrosis. Despite extensive search for 
diseases associated with nephrocalcinosis aetiology could not be elucidated. All these findings 
led to the diagnosis of iatrogenic Cushing syndrome. Consequently, dosage of dexamethasone 
drops was reduced and eventually stopped (Table). At the age of 12 months, he showed catch-
up growth (Figure 1A) and absence of cushingoid features (Figure 1B). On laboratory 
evaluation ACTH and cortisol levels were normalised (ACTH 58 pg/ml; cortisol 319 nmol/l).  
 
Discussion  
The diagnosis of iatrogenic Cushing syndrome may be fairly obvious in patients 
receiving systemic administration of glucocorticoids. However, it may be much more difficult 
in children treated with locally delivered steroids e.g. by inhalation or in dermatological 
preparations (5, 10). Cushing syndrome as a result of topical ocular steroids is a rare and 
probably underreported complication in infants and children. To the best of our knowledge, 
only four cases have been reported (3, 8, 9, 11) [PubMed was searched for the following 
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keywords: ((("Cushing Syndrome"[Mesh] OR (Cushing AND Syndrome)) AND 
(("Ophthalmic Solutions"[Mesh] OR "Ophthalmic Solutions" [Pharmacological Action] OR 
(Ophtalmic AND Solutions) OR (eye AND drops)) AND ("Glucocorticoids"[Mesh] OR 
Glucocorticoids))]. There are several ophthalmologic indications for topical ocular steroid 
treatment in children, one of the most important being the postoperative care after lensectomy 
in infants with congenital cataract. In order to prevent serious intraocular inflammations like 
fibrinous uveitis, which is more common in infants than in adults, frequent application of 
glucocorticoid-containing eye drops is essential. An intense therapy scheme is often pursued 
for weeks to months. Systemic absorption of glucocorticoid-containing eye drops depends on 
drug concentration, chemical formulation and composition of the vehicle. In general, mucous 
membranes including the conjunctiva are highly absorptive areas. In addition, ocular drops 
are not only absorbed by the conjunctiva but also by the nasal mucosa via lacrimal drainage 
system (7). Of note, systemic absorption of mydriatic eye drops (phenylephrine or 
cyclopenthale) associated with arterial hypertension or generalized seizures was previously 
reported in children (2, 4) 
Our patient received standard dexamethasone-containing eye drops of 0.1% (1.1 
mg/ml). For the first two weeks of treatment the approximate daily dose was 1.3 mg 
dexamethasone per day (~5.2 mg/m2) corresponding to a cortisol equivalent of  ~100 mg/m2 
(Table). In comparison, endogenous cortisol secretion rate in healthy infants/children is 
estimated to be between 6-14 mg/m2 per day (6). A decrease in growth velocity is observed as 
soon as daily dosages exceed a cortisol equivalent of 20 to 25 mg/m2/24 hours (1). Indeed 
growth velocity in our patient dropped early after initiation of ocular dexamethasone 
treatment resulting in a height below the 3rd percentile. 
In conclusion, topical steroid preparation may cause iatrogenic Cushing syndrome. 
Therefore, physicians prescribing topical steroids should be aware of such complication and 
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closely follow these patients. Moreover, withdrawal from long-term treatment may cause 
adrenal insufficiency demanding a careful weaning of topical steroids. 
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Figure Legends 
 
Figure 1 
(A) Longitudinal growth and weight curves of the patient. (B) Patient at the age of 3 months 
(2 months under dexamethasone treatment; left) and at the age of 1 year (right). Consent to 
show photographs was obtained from both parents. 
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Table 1 Dexamethasone dose application over time 
 
Weeks after 
cataract extraction  
Dexamethasone dose 
(drop/eye/day) 
Dexamethasone dose 
(mg/day) 
Cortisol equivalent 
0-2 12 1.3 94 mg/m2 
3-4 6 0.7 47 mg/m2 
5-6 5 0.6 39 mg/m2 
7-8 4 0.4 33 mg/m2 
9-10 3 0.3 24 mg/m2 
11-14 2 0.2 16 mg/m2 
 175 
Figure 1
A B
cm
kg
Dexamethasone
therapy
Age (months) 
3 months 1 year
